A citation-based method for searching scientific literature

Neil H Shear, Keith A Betts, Ahmed M Soliman, Avani Joshi, Yan Wang, Jing Zhao, Paolo Gisondi, Ranjeeta Sinvhal, April W Armstrong. J Am Acad Dermatol 2021
Times Cited: 5







List of co-cited articles
48 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.
April W Armstrong, Luis Puig, Avani Joshi, Martha Skup, David Williams, Junlong Li, Keith A Betts, Matthias Augustin. JAMA Dermatol 2020
68
80

Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
Richard B Warren, Melinda Gooderham, Russel Burge, Baojin Zhu, David Amato, Karen Huayu Liu, David Shrom, Jiaying Guo, Alan Brnabic, Andrew Blauvelt. J Am Acad Dermatol 2020
23
60

Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.
Najeeda Yasmeen, Laura M Sawyer, Kinga Malottki, Lars-Åke Levin, Eydna Didriksen Apol, Gregor B Jemec. J Dermatolog Treat 2022
17
60

National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study.
Rosa Parisi, Ireny Y K Iskandar, Evangelos Kontopantelis, Matthias Augustin, Christopher E M Griffiths, Darren M Ashcroft. BMJ 2020
133
60

Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.
S K Mahil, M C Ezejimofor, L S Exton, L Manounah, A D Burden, L C Coates, M de Brito, A McGuire, R Murphy, C M Owen,[...]. Br J Dermatol 2020
22
60


Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Yayoi Tada, Rei Watanabe, Hisashi Noma, Yasumasa Kanai, Takanobu Nomura, Kenji Kaneko. J Dermatol Sci 2020
12
60

Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis.
Weiguang Xue, Paranjoy Saharia, Emma Gray, Shoghag Khoudigian-Sinani, Véronique Gaudet, Martin Barbeau, Kim Papp. J Cutan Med Surg 2020
5
60

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Sivem Afach, Liz Doney, Corinna Dressler, Camille Hua, Canelle Mazaud, Céline Phan, Carolyn Hughes, Dru Riddle,[...]. Cochrane Database Syst Rev 2020
73
60

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Liz Doney, Corinna Dressler, Camille Hua, Carolyn Hughes, Luigi Naldi, Sivem Afach, Laurence Le Cleach. Cochrane Database Syst Rev 2021
18
40


Indirect comparison of anti-interleukin 17 targeted biological treatments for moderate-to-severe psoriasis.
Rocío Díaz Acedo, Mercedes Galvan Banqueri, Esther Márquez Saavedra. J Clin Pharm Ther 2020
2
100

A Systematic Review With Network Meta-Analysis of the Available Biologic Therapies for Psoriatic Disease Domains.
Tiago Torres, Anabela Barcelos, Paulo Filipe, João Eurico Fonseca. Front Med (Lausanne) 2021
5
40

Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method.
U Mrowietz, R B Warren, C L Leonardi, D Saure, H Petto, S Hartz, M Dossenbach, K Reich. J Eur Acad Dermatol Venereol 2021
4
50

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Giao Do, Camille Hua, Canelle Mazaud, Catherine Droitcourt, Carolyn Hughes, John R Ingram, Luigi Naldi,[...]. Cochrane Database Syst Rev 2017
147
40

Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis.
Guomei Xu, Meng Xia, Chenjie Jiang, Ying Yu, Guomi Wang, Jiaojiao Yuan, Xingwu Duan. J Pharmacol Sci 2019
19
40

The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis.
Laura Sawyer, Iain Fotheringham, Emily Wright, Najeeda Yasmeen, Carl Gibbons, Anders Holmen Møller. J Dermatolog Treat 2018
21
40



Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
Laura M Sawyer, Kinga Malottki, Celia Sabry-Grant, Najeeda Yasmeen, Emily Wright, Anne Sohrt, Emma Borg, Richard B Warren. PLoS One 2019
69
40




Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis.
Shanshan Xu, Xing Gao, Jixiang Deng, Jiajia Yang, Faming Pan. J Dtsch Dermatol Ges 2021
3
66

Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses.
Richard B Warren, Kyoungah See, Russel Burge, Ying Zhang, Alan Brnabic, Gaia Gallo, Alyssa Garrelts, Alexander Egeberg. Dermatol Ther (Heidelb) 2020
18
40

A Systematic Literature Review and Bucher Indirect Comparison: Tildrakizumab versus Guselkumab.
Kristian Garn Du Jardin, Pepi Hurtado Lopez, Mette Lange, Rachael McCool, Silvia Maeso Naval, Sandra Quickert. J Health Econ Outcomes Res 2020
4
50


Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
N Woolacott, N Hawkins, A Mason, A Kainth, Z Khadjesari, Y Bravo Vergel, K Misso, K Light, R Chalmers, M Sculpher,[...]. Health Technol Assess 2006
119
40

Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
Kristian Reich, Rodney Sinclair, Graeme Roberts, Christopher E M Griffiths, Maggie Tabberer, Jonathan Barker. Curr Med Res Opin 2008
37
40

Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.
April W Armstrong, Keith A Betts, James E Signorovitch, Murali Sundaram, Junlong Li, Arijit X Ganguli, Eric Q Wu. Curr Med Res Opin 2018
18
40

Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review.
Andrew Blauvelt, Russel Burge, William Malatestinic, Alan Brnabic, Jiaying Guo, Manju Janardhanan, Baojin Zhu. J Manag Care Spec Pharm 2021
2
100

Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
L M Sawyer, L Cornic, L Å Levin, C Gibbons, A H Møller, G B Jemec. J Eur Acad Dermatol Venereol 2019
53
40



Bimekizumab versus Secukinumab in Plaque Psoriasis.
Kristian Reich, Richard B Warren, Mark Lebwohl, Melinda Gooderham, Bruce Strober, Richard G Langley, Carle Paul, Dirk De Cuyper, Veerle Vanvoorden, Cynthia Madden,[...]. N Engl J Med 2021
31
40


Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Diamant Thaçi, Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Sophie Hugot, Ruquan You,[...]. J Am Acad Dermatol 2015
353
40

Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
40

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Kenneth B Gordon, Peter Foley, James G Krueger, Andreas Pinter, Kristian Reich, Ronald Vender, Veerle Vanvoorden, Cynthia Madden, Katy White, Christopher Cioffi,[...]. Lancet 2021
43
40

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Kristian Reich, Kim A Papp, Andrew Blauvelt, Richard G Langley, April Armstrong, Richard B Warren, Kenneth B Gordon, Joseph F Merola, Yukari Okubo, Cynthia Madden,[...]. Lancet 2021
44
40

Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.
Carle Paul, Christopher E M Griffiths, Peter C M van de Kerkhof, Lluís Puig, Yves Dutronc, Carsten Henneges, Martin Dossenbach, Kristin Hollister, Kristian Reich. J Am Acad Dermatol 2019
54
40

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Kristian Reich, April W Armstrong, Richard G Langley, Susan Flavin, Bruce Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt. Lancet 2019
121
40

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth Gordon, Jolanta Weglowska, Lluis Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco Kerdel,[...]. N Engl J Med 2015
485
40

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley,[...]. Lancet 2018
258
40

Bimekizumab versus Adalimumab in Plaque Psoriasis.
Richard B Warren, Andrew Blauvelt, Jerry Bagel, Kim A Papp, Paul Yamauchi, April Armstrong, Richard G Langley, Veerle Vanvoorden, Dirk De Cuyper, Christopher Cioffi,[...]. N Engl J Med 2021
26
40


Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Stephen Tyring, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Ronald Vender, Sophie Hugot,[...]. J Am Acad Dermatol 2017
190
40


Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.
Philip J Mease, Iain B McInnes, Lai-Shan Tam, Kiefer Eaton, Steve Peterson, Agata Schubert, Soumya D Chakravarty, Anna Parackal, Chetan S Karyekar, Sandhya Nair,[...]. Rheumatology (Oxford) 2021
12
20

Comparison of two independent systematic reviews of trials of recombinant human bone morphogenetic protein-2 (rhBMP-2): the Yale Open Data Access Medtronic Project.
Jeffrey Low, Joseph S Ross, Jessica D Ritchie, Cary P Gross, Richard Lehman, Haiqun Lin, Rongwei Fu, Lesley A Stewart, Harlan M Krumholz. Syst Rev 2017
9
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.